LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 12 of 15: Mean cell count and mean normalized growth rate inhibition values across biological replicate 2. - Dataset (ID:20249)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Timepoint | Timepoint Unit | Mean Total Cell Count Before Treatment | Mean Total Cell Count After Treatment | Mean Total Control Cell Count | Mean Relative Cell Count | Mean Normalized Growth Rate Inhibition Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | OSI-027 | 3.33 | uM | LJP6 | 72 | hr | 2543 | 2265 | 5418 | 0.4182 | -0.1012 |
| SK-BR-3 | OSI-027 | 10 | uM | LJP6 | 72 | hr | 2543 | 2120 | 5418 | 0.3917 | -0.1535 |
| SK-BR-3 | WYE-125132 | 0.12 | uM | LJP6 | 72 | hr | 2543 | 2145 | 5418 | 0.3955 | -0.1462 |
| SK-BR-3 | WYE-125132 | 0.37 | uM | LJP6 | 72 | hr | 2543 | 2034 | 5418 | 0.3754 | -0.1860 |
| SK-BR-3 | Seliciclib | 0.04 | uM | LJP5 | 72 | hr | 2543 | 5757 | 5752 | 1.0010 | 1.0016 |
| SK-BR-3 | Seliciclib | 0.12 | uM | LJP5 | 72 | hr | 2543 | 5868 | 5752 | 1.0202 | 1.0343 |
| SK-BR-3 | Seliciclib | 1.11 | uM | LJP5 | 72 | hr | 2543 | 5394 | 5752 | 0.9377 | 0.8937 |
| SK-BR-3 | Seliciclib | 3.33 | uM | LJP5 | 72 | hr | 2543 | 4738 | 5752 | 0.8238 | 0.6963 |
| SK-BR-3 | AT-7519 | 0.12 | uM | LJP6 | 72 | hr | 2543 | 3234 | 5418 | 0.5975 | 0.2473 |
| SK-BR-3 | AT-7519 | 0.37 | uM | LJP6 | 72 | hr | 2543 | 2056 | 5418 | 0.3799 | -0.1769 |
| SK-BR-3 | AT-7519 | 3.33 | uM | LJP6 | 72 | hr | 2543 | 913 | 5418 | 0.1686 | -0.6092 |
| SK-BR-3 | AT-7519 | 10 | uM | LJP6 | 72 | hr | 2543 | 697 | 5418 | 0.1286 | -0.6947 |
| SK-BR-3 | AZD7762 | 1.11 | uM | LJP6 | 72 | hr | 2543 | 1345 | 5418 | 0.2480 | -0.4431 |
| SK-BR-3 | AZD7762 | 3.33 | uM | LJP6 | 72 | hr | 2543 | 1307 | 5418 | 0.2414 | -0.4570 |
| SK-BR-3 | AZD8055 | 0.04 | uM | LJP6 | 72 | hr | 2543 | 2013 | 5418 | 0.3717 | -0.1933 |
| SK-BR-3 | AZD8055 | 0.12 | uM | LJP6 | 72 | hr | 2543 | 1763 | 5418 | 0.3254 | -0.2859 |
| SK-BR-3 | AZD8055 | 3.33 | uM | LJP6 | 72 | hr | 2543 | 1791 | 5418 | 0.3303 | -0.2762 |
| SK-BR-3 | AZD8055 | 10 | uM | LJP6 | 72 | hr | 2543 | 1586 | 5418 | 0.2925 | -0.3523 |
| SK-BR-3 | Sorafenib | 0.12 | uM | LJP6 | 72 | hr | 2543 | 5536 | 5418 | 1.0222 | 1.0417 |
| SK-BR-3 | Sorafenib | 0.37 | uM | LJP6 | 72 | hr | 2543 | 5574 | 5418 | 1.0293 | 1.0551 |
| SK-BR-3 | CP466722 | 0.12 | uM | LJP5 | 72 | hr | 2543 | 5836 | 5752 | 1.0148 | 1.0248 |
| SK-BR-3 | CP466722 | 0.37 | uM | LJP5 | 72 | hr | 2543 | 5746 | 5752 | 0.9990 | 0.9980 |
| SK-BR-3 | CP466722 | 3.33 | uM | LJP5 | 72 | hr | 2543 | 5979 | 5752 | 1.0394 | 1.0665 |
| SK-BR-3 | Barasertib | 3.33 | uM | LJP5 | 72 | hr | 2543 | 2030 | 5752 | 0.3530 | -0.1742 |
| SK-BR-3 | Barasertib | 1.11 | uM | LJP5 | 72 | hr | 2543 | 2087 | 5752 | 0.3628 | -0.1549 |